Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 5Thoracic 3Gynecologic 3Breast 3Other hematologic neoplasm 2CNS 2Plasma cell 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 1

Interventions

Carboplatin 509Cisplatin 410Pemetrexed 399Radiotherapy 282Docetaxel 244Paclitaxel 227pembrolizumab 225Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 176Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Vinorelbine 90Magnetic Resonance Spectroscopy 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Pharmacogenomic Variants × Thoracic × Clear all
NCT03582124 2026-02-10

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Stanford University

Phase 1/2 Recruiting
30 enrolled
Thoracic

Lung Neoplasms

NCT03225664 2026-01-16

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
37 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03520842 2023-08-01

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Stanford University

Phase 2 Completed
22 enrolled 20 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡